1
|
Pistillucci G, Ciorra AA, Sciacca V, Raponi M, Rossi R, Veltri E. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab]. Clin Ter 2016; 166:e67-71. [PMID: 25756270 DOI: 10.7417/ct.2015.1812] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Adjuvant trastuzumab with chemotherapy is the treatment of choice for patients with human epidermal growth factor receptor positive (HER2+) breast cancer and improves the outcome of patients with early breast cancer. However, it is potentially cardiotoxic and there are no validated methods of early detection of cardiotoxicity from trastuzumab following anthracycline-based chemotherapy. Currently, changes in left ventricular ejection fraction (LVEF) are assessed but this approach has limited sensitivity and specificity. Early identification of patients at risk for cardiotoxic effects is a primary goal for both cardiologists and oncologists. Plasma markers such as b-type natriuretic peptide (BNP - an index of elevated filling pressure) and troponin I (TnI - an index of cardiomyocyte damage) may be used to identify the risk of developing cardiac dysfunction during treatment. In this review, we discuss if TnI and/or BNP could be used to help the prevention or treatment of cardiac dysfunction at the earliest possible time.
Collapse
Affiliation(s)
- G Pistillucci
- U.O.C. Oncologia Medica Ospedale Santa Maria Goretti di Latina
| | - A A Ciorra
- U.O.C. Oncologia Medica Ospedale Santa Maria Goretti di Latina
| | - V Sciacca
- U.O.C. Oncologia Medica Ospedale Santa Maria Goretti di Latina
| | - M Raponi
- U.O.C. Cardiologia Ospedale Santa Maria Goretti di Latina, Italia
| | - R Rossi
- U.O.C. Oncologia Medica Ospedale Santa Maria Goretti di Latina
| | - E Veltri
- U.O.C. Oncologia Medica Ospedale Santa Maria Goretti di Latina
| |
Collapse
|
2
|
Busco S, Sperduti I, Pistillucci G, Cirino C, Salesi N, Sciacca V, Di Cocco B, Ciorra A, Di Palma T, Rossi R, Calabretta F, Cardillo F, Fattoruso S, Fiori M, Burchi D, Pannozzo F, Albertoni F, Veltri E. Evaluation of diagnostic investigations used in breast cancer patients resident in Latina province during three years follow up after diagnosis. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Ciorra AA, Sciacca V, Pistillucci G, Rossi R, Di Palma T, Travaini S, Ricci F, Veltri E. Unusual endotracheal and breast metastasis from renal clear cell carcinoma: a case report. Clin Ter 2014; 164:e515-7. [PMID: 24424234 DOI: 10.7417/ct.2013.1648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We report a case of a woman affected by a metastatic renal clear cell carcinoma who showed unusual metastasis into the trachea and in the right breast 17 years and 21 years after nephrectomy respectively. Two endotracheal metastasis were identified during rigid bronchoscophy and were treated with endotracheal electro-surgery. Solitary metastasis in the right breast was identified by a mammography that revealed a dense mass of 1.5 cm at lower outer quadrant and she underwent to a right breast quadrantectomy. Histological examination showed a clear cell renal carcinoma metastasis as for the trachea as for the breast mass.
Collapse
Affiliation(s)
- A A Ciorra
- U.O.C. Oncologia Medica, Ospedale Santa Maria Goretti di Latina, Italia
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Luqini A, Pace R, Capparella V, Ciorra A, Sciacca V, Pistillucci G, Rossi R. 8035 POSTER The Combination of Weekly Carboplatin and Paclitaxel is Active and Tolerated for the Treatment of Advanced Ovarian Cancer in Elderly Patients. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72123-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
5
|
Lugini A, Pace R, Rauco A, Sciacca V, Pistillucci G, Ciorra A, Rossi R, Capparella V. 3020 POSTER Role of Paroxetine in the Treatment Anticipatory Nausea and Vomiting in Cancer Patients: Multicentre Experience. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71093-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
De Placido S, Lopez M, Carlomagno C, Paoletti G, Palazzo S, Manzione L, Iannace C, Ianniello GP, De Vita F, Ficorella C, Farris A, Pistillucci G, Gemini M, Cortesi E, Adamo V, Gebbia N, Palmeri S, Gallo C, Perrone F, Persico G, Bianco AR. Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. Br J Cancer 2005; 93:896-904. [PMID: 16222322 PMCID: PMC2361663 DOI: 10.1038/sj.bjc.6602800] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 08/02/2005] [Accepted: 08/25/2005] [Indexed: 01/25/2023] Open
Abstract
The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival advantage. The hazard ratio (HR) of relapse was 0.89 (95% confidence intervals (CI): 0.73-1.09) for patients receiving FA and 0.99 (95% CI 0.80-1.21) for those receiving LEV; corresponding HRs of death were 1.02 (95% CI: 0.80-1.30) and 0.94 (95% CI 0.73-1.20). Nonhaematological toxicity (all grade vomiting, diarrhoea, mucositis, congiuntivitis, skin, fever and fatigue) was significantly worse with FA, while all other toxicities were similar. In the present trial, there was no evidence that the addition of FA or LEV significantly prolongs DFS and OAS of radically resected colorectal cancer patients.
Collapse
Affiliation(s)
- S De Placido
- Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II, Napoli, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Lalle M, Pistillucci G, Antimi M, D'Aprile M. Epoetin alfa 40000 U once weekly and intravenous iron supply in solid tumor patients: early increase of hemoglobin level during chemotherapy. J Exp Clin Cancer Res 2005; 24:197-201. [PMID: 16110751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The objective of this observational study was the early evaluation of the impact, a week after the first administration of epoetin alfa 40000 U once weekly and i.v. dose of 62.5 mg sodium ferric gluconate for seven days in improving hemoglobin levels in cancer patients affected by mild/moderate or severe anemia during chemotherapy. Twenty patients affected by solid tumors who received epoetin alfa 40000 U once weekly and daily i.v. sodium ferric gluconate for one week were evaluated: 90% of the patients showed hemoglobin increase, with a median level of hemoglobin increase of 0.73 g/L from baseline, and 50% of them showing a hemoglobin increase > 1 gr/L. The treatment was well tolerated and no adverse event was observed. The early increase of hemoglobin level from baseline is interesting and suggestive for the possibility of achieving an adequate hemoglobin level with a short-term treatment. It is still necessary to further explore the real need of iron supplementation to maintain adequate erythropoiesis prior and during epoetin therapy.
Collapse
Affiliation(s)
- M Lalle
- Unità Operativa Complessa di Oncologia Medica, Ospedale S. Eugenio, Rome, Italy.
| | | | | | | |
Collapse
|
8
|
De Placido S, De Laurentiis M, De Lena M, Lorusso V, Paradiso A, D'Aprile M, Pistillucci G, Farris A, Sarobba MG, Palazzo S, Manzione L, Adamo V, Palmeri S, Ferraù F, Lauria R, Pagliarulo C, Petrella G, Limite G, Costanzo R, Bianco AR. A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. Br J Cancer 2005; 92:467-74. [PMID: 15668708 PMCID: PMC2362097 DOI: 10.1038/sj.bjc.6602355] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
The sequential doxorubicin → CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A → CMF or arms a+c vs b+d) and (2) the effect of adding GT after chemotherapy (arms a+b vs c+d). At a median follow-up of 72 months, A → CMF as compared to CMF significantly improved disease-free survival (DFS) with a multivariate hazard ratio (HR)=0.740 (95% confidence interval (CI): 0.556–0.986; P=0.040) and produced a nonsignificant improvement of overall survival (OS) (HR=0.764; 95% CI: 0.489–1.193). The addition of GT after chemotherapy significantly improved DFS (HR=0.74; 95% CI: 0.555–0.987; P=0.040), with a nonsignificant improvement of OS (HR=0.84; 95% CI: 0.54–1.32). A → CMF is superior to CMF. Adding GT after chemotherapy is beneficial for premenopausal node-positive patients.
Collapse
Affiliation(s)
- S De Placido
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - M De Laurentiis
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - M De Lena
- See Appendix A for a complete list of co-authors and Institutions
| | - V Lorusso
- See Appendix A for a complete list of co-authors and Institutions
| | - A Paradiso
- See Appendix A for a complete list of co-authors and Institutions
| | - M D'Aprile
- See Appendix A for a complete list of co-authors and Institutions
| | - G Pistillucci
- See Appendix A for a complete list of co-authors and Institutions
| | - A Farris
- See Appendix A for a complete list of co-authors and Institutions
| | - M G Sarobba
- See Appendix A for a complete list of co-authors and Institutions
| | - S Palazzo
- See Appendix A for a complete list of co-authors and Institutions
| | - L Manzione
- See Appendix A for a complete list of co-authors and Institutions
| | - V Adamo
- See Appendix A for a complete list of co-authors and Institutions
| | - S Palmeri
- See Appendix A for a complete list of co-authors and Institutions
| | - F Ferraù
- See Appendix A for a complete list of co-authors and Institutions
| | - R Lauria
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - C Pagliarulo
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - G Petrella
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - G Limite
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - R Costanzo
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
| | - A R Bianco
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy
- See Appendix A for a complete list of co-authors and Institutions
- Department Molecular and Clinical Oncology and Endocrinology, University Federico II, Via S Pansini 5, Napoli 80131, Italy. E-mail:
| |
Collapse
|
9
|
Gridelli C, D'Aprile M, Palmeri S, Curcio C, Rossi A, Gebbia V, Veltri E, Pepe R, Pistillucci G, Bianco AR. Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer. Am J Clin Oncol 1996; 19:589-91. [PMID: 8931678 DOI: 10.1097/00000421-199612000-00012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In attempt to develop a new chemotherapeutic regimen including carboplatin (CBDCA), epirubicin (EPI), and VP-16 in extensive small cell lung cancer, with a higher dose intensity compared with previous experience of our group, we determined the maximum tolerated dose (MTD) of VP-16 when administered in association with CBDCA (300 mg/ m2, i.v., day 1) and EPI (75 mg/m2, i.v., day 1), recycling chemotherapy every 3 weeks, with the support of granulocyte-colony-stimulating factor (G-CSF). A total of 15 patients received three dose levels of VP-16 (mg/m2, i.v., daily on days 1-3): 100 (three patients), 120 (six), and 140 (six). G-CSF was administered subcutaneously at the dose of 5 micrograms/kg/day on days 6-15 of each chemotherapy course. The MTD was established at 140 mg/m2 and myelotoxicity, grade 4 neutropenia with death for sepsis in one case and grade 3 thrombocytopenia in three cases, was dose limiting. The recommended dose of VP-16 for a phase II study is 140 mg/m2.
Collapse
Affiliation(s)
- C Gridelli
- Division of Medical Oncology, Faculty of Medicine, Federico II University, Naples, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|